secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outset Medical, Inc. (OM)
CIK:        0001484612
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001193125-25-036741
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outset Medical receives second Nasdaq delisting notice; FY2024 revenue $113.7M, down 13%
--------------------------------------------------------------------------------

- Nasdaq notified Outset on Feb 24, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure period until Aug 25, 2025.
- Stockholders to vote on reverse stock split (ratio 1:10 to 1:15) at special meeting March 5, 2025.
- FY2024 total revenue $113.7M, down 12.8% from $130.4M in 2023; product revenue fell 21.7% to $81.0M.
- Net loss narrowed to $128.0M ($2.46 loss per share) from $172.8M ($3.48) in 2023; cash rose to $124.0M from $68.5M.
- Term loan balance increased to $197.4M from $130.1M; accumulated deficit reached $1.09B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484612/000119312525036741/0001193125-25-036741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484612/000119312525036741/d122047d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-036741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer